General Medicine · Medical Literature
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Abstract
New England Journal of Medicine, Volume 395, Issue 5, Page 421-423, July 30, 2026.
Clinical relevance
When legislative and executive branches of government fail to adequately regulate products that pose health risks — including pharmaceuticals, tobacco, and social media platforms — can civil litigation serve as an effective substitute or complementary mechanism to protect public health? __SNAPSHOT__ {"studyDesign":"Perspective (expert opinion / narrative commentary) — not an original research study or systematic review","setting":"Not applicable (commentary piece); author affiliated with Harvard Medical School and the Program on Regulation, Therapeutics, and Law at Harvard Medical School and Brigham and Women's Hospital","sampleSize":"Not applicable","population":"Not applicable; commentary addresses broad populations harmed by consumer products including pharmaceuticals, tobacco, and social media platforms","intervention":"Civil litigation as a public health protection mechanism when regulatory agencies and legislative bodies are unable or unwilling to act","comparator":"Government regulatory action (legislative, executive/agency-based) as the traditional primary protection mechanism","primaryOutcome":"Not applicable; the piece examines the historical record, potential, and limitations of litigation as a public health tool across product categories","followUp":"Not applicable","fundingSource":"Not reported"}
Key findings
This is an expert Perspective piece, not an empirical study; no original quantitative data, effect sizes, p-values, or confidence intervals are reported. The central argument, as summarized by the journal, is that recent lawsuits against social media companies — analogous to past litigation against drug and tobacco manufacturers — demonstrate that when legislative and executive branches of government fail to protect public health, the courts may serve a meaningful compensatory role. The author draws on historical examples of product liability and public-nuisance litigation (tobacco, pharmaceuticals) to assess whether the judiciary can function as a structural backstop for public health protection in periods of regulatory retreat. No statistical findings are presented; all conclusions are qualitative and based on the author's legal-historical analysis and clinical-policy expertise.
Practice implications
IMPORTANT LIMITATION: Only the abstract and journal-level summary are available for this analysis; the full text of the Perspective was not accessible. Conclusions are therefore based on the stated thesis and publicly available editorial description, and may not fully capture the nuance, caveats, or sub-arguments of the complete piece. This is a Perspective — the lowest tier of evidence in the evidence-based medicine hierarchy — representing one expert's informed opinion rather than a synthesized body of empirical evidence. It does not establish causal relationships, measure intervention efficacy, or generate data applicable to individual patient care. Its relevance to clinical practice is primarily contextual and policy-oriented: clinicians practicing in regulatory environments where agency oversight of harmful products has been weakened may find the author's framework useful for understanding the medicolegal landscape. The piece does not provide guidance on patient-level clinical decision-making. Findings (such as they are) apply broadly to health policy stakeholders, legal practitioners, and clinicians engaged in advocacy or public health, rather than to specific patient populations. The author's conclusions should be interpreted as hypothesis-generating and advocacy-oriented, not as practice-changing evidence. __LIMITATIONS__ 1. Study design: Expert opinion/Perspective; subject to individual author bias and selective use of historical examples without systematic review methodology. 2. No primary data: All conclusions are qualitative; no empirical evidence is generated or synthesized with formal methods. 3. Only the abstract is available for review, precluding assessment of the completeness of the author's argument, the quality of cited evidence, or the acknowledgment of counterarguments within the full text. 4. Generalizability: The legal framework discussed is primarily U.S.-centric; applicability to other jurisdictions is uncertain. 5. Conflict of interest and funding: Not reported; the author's institutional affiliation with a program focused on regulation, therapeutics, and law may reflect an advocacy orientation. 6. Temporal scope: Historical litigation examples (tobacco, opioids) may not translate directly to emerging product categories such as social media platforms given significant differences in legal standing, causation standards, and First Amendment protections. 7. No patient-centered outcomes measured. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ This NEJM Perspective by Jerry Avorn argues that civil litigation — as demonstrated by historical actions against tobacco and pharmaceutical manufacturers, and more recently against social media companies — can function as a public health protection mechanism when government regulatory capacity fails. The piece offers a policy-level framework rather than clinical evidence, and does not alter patient management or prescribing practice. Clinicians engaged in health policy, advocacy, or medicolegal work may find the historical and legal parallels drawn here contextually informative.